3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes John Chappell of BlockApps, Kyra Doolan of Texas HALO Fund, and Shaun Noorian of Empower Pharmacy. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from venture capital to pharmacy — recently making headlines in Houston innovation.

John Chappell, director of energy business development at BlockApps

Siloed data, lack of consistency, and confusing regulations are all challenges blockchain can address, says this expert. Photo courtesy

Houston has all the potential to lead the energy transition — it just needs to make sure it has all the right ingredients. According to John Chappell, a key ingredient is blockchain. He explains in a guest article for InnovationMap.

"Houston has earned its title as the Energy Transition Capital of the world, and now it has an opportunity to be a global leader of technology innovation when it comes to carbon emissions reporting," Chappell writes. "The oil and gas industry has set ambitious goals to reduce its carbon footprint, but the need for trustworthy emissions data to demonstrate progress is growing more apparent — and blockchain may hold the keys to enhanced transparency." Click here to read more.

Kyra Doolan, managing director at Texas HALO Fund

Kyra Doolan joins the Houston Innovators Podcast to discuss the huge opportunities for innovation within femtech. Photo via LinkedIn

When venture capitalist and angel investing expert Kyra Doolan started navigating her own fertility journey, her eyes were opened to a huge market opportunity across femtech. As managing director at Houston-based Texas HALO Fund, she took these opportunities to her team of investors.

"A lot of the issues that face women, are things that are not talked about," she says on this week's episode of the Houston Innovators Podcast, referencing things like miscarriage, injury during childbirth, etc. "For a lot time, women just sat back if they had these issues, and they kept it to themselves, so those problems weren't being addressed."

Doolan says she and other women aren't taught how to manage their own fertility journey, but it doesn't have to be that way. Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy

Empower Pharmacy has opened its new 86,000-square-foot facility features innovative technology for purifying water, automation, and more. Photo courtesy of Empower Pharmacy

Houston-based Empower Pharmacy has celebrated the grand opening of its new $55 million, 86,000-square-foot facility that includes extensive automation, a top-of-the line cleanroom, and equipment that generates purified water, clean steam, and clean compressed air. The space also features a warehouse capable of storing at least nine months of raw pharmaceutical ingredients to minimize supply chain problems.

"This innovative facility, combined with our more than 500 dedicated employees, enables us to increase our operational capacity, allowing us to prepare thousands of custom prescriptions each day for millions of patients across the country," Shaun Noorian, founder and CEO of Empower Pharmacy, says in a news release. "We are setting a new standard for compounded medicine, striving to achieve a superior pharmaceutical experience, from order placement to delivery."

The new Empower Pharmacy facility, at 7601 N. Sam Houston Parkway W., opened earlier this month. Click here to read more.

The new 86,000-square-foot facility features innovative technology for purifying water, automation, and more. Photo courtesy of Empower Pharmacy

Innovative Houston-based pharmacy debuts new $55M facility

now open

Adding heft to Houston's health care economy, Empower Pharmacy on August 26 publicly debuted what the company bills as North America's most technologically advanced compounding pharmacy.

Highlights of the new $55 million, 86,000-square-foot facility include extensive automation, a top-of-the line cleanroom, and equipment that generates purified water, clean steam, and clean compressed air. The space also features a warehouse capable of storing at least nine months of raw pharmaceutical ingredients to minimize supply chain problems.

Houston-based Empower Pharmacy supplies pharmaceutical products to more than 1 million patients and 2,000 institutions across the country each year.

As described by the U.S. Food and Drug Administration (FDA), drug compounding involves combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. Compounding includes the blending of two or more drugs. Compounded drugs are not FDA-approved.

The new Empower Pharmacy facility, at 7601 N. Sam Houston Parkway W., opened earlier this month.

"This innovative facility, combined with our more than 500 dedicated employees, enables us to increase our operational capacity, allowing us to prepare thousands of custom prescriptions each day for millions of patients across the country," Shaun Noorian, founder and CEO of Empower Pharmacy, says in a news release. "We are setting a new standard for compounded medicine, striving to achieve a superior pharmaceutical experience, from order placement to delivery."

Empower Pharmacy has opened its new space — with an additional facility in the works for next year. Photo courtesy of Empower

Next year, Empower Pharmacy plans to open a second facility mirroring the new facility, but this one will operate with a federal 503B license. The license will let Empower Pharmacy make compounding medicines and sell them directly to hospitals, doctor's offices and other health care institutions.

Brunner calls Empower Pharmacy "a leader in pharmacy compounding, pushing the envelope in terms of innovation and technology. With this new state-of-the-art facility, they're not only increasing capacity, but also elevating compliance and safety and — most importantly — the care they provide patients."

In July, Noorian told InnovationMap that he started Empower Pharmacy out of frustration with medication he was getting from a compounding pharmacy in Houston. At the time, he was a hydraulic fracturing field engineer at Schlumberger.

Noorian initially operated his pharmacy from 100 square feet of leased space in a doctor's office.

"Slowly but surely, patients and prescribers around the area were very happy with the level of service and quality that they were receiving from our pharmacy. And we would get more requests through simple word of mouth and reputation," Noorian recalled. "We grew pretty quickly out of that space and then built out a 1,500-square-foot space in a shopping center a couple of years later."

Several more locations and expansions followed, leading to the opening of the 86,000-square-foot facility.

"We've always concentrated on — since the inception of the company — quality, service, and cost," Noorian told InnovationMap. "And we're always working to figure out how to increase quality, how to decrease costs, and how to make it easier and more convenient for our customers to use us."

This week's roundup of Houston innovators includes Robert Kester of Honeywell Rebellion, Serafina Lalany of Houston Exponential, and Shaun Noorian of Empower Pharmacy. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from oil and gas tech to pharmaceuticals — recently making headlines in Houston innovation.

Robert Kester, president and general manager at Honeywell Rebellion

Robert Kester, founder of Rebellion Photonics and president and general manager at Honeywell

Robert Kester joins the Houston Innovators Podcast to discuss his entrepreneurial journey. Photo courtesy of Honeywell

Robert Kester co-founded Rebellion Photonics in 2010. After several years of developing the device that could be used to automate the process and improve safety on oil and gas sites, Kester and his team saw a rising need for the tech — which also meant a need for Rebellion to scale quickly. In 2019, Rebellion exited in an acquisition by Honeywell.

"For us it just made sense that we could team up with Honeywell and figure out how we could scale this thing globally and quickly, so that we could help be a solution for climate change," Kester continues.

Now, as president and general manager at Honeywell Rebellion, Kester still works on his technology under the umbrella of the Honeywell brand. He joined the Houston Innovators Podcast last week to discuss the transition and what he's focused on now. Click here to read more and stream the episode.

Serafina Lalany, interim president of Houston Exponential

Serafina Lalany, vice president of operations at Houston Exponential

Last week, Serafina Lalany is acting as interim identifies the organization's new leader. Photo courtesy of Serafina Lalany

Serafina Lalany, vice president of operations at Houston Exponential, will act as interim executive director for the organization after Harvin Moore, who has served as president of HX since June 2019, announced his resignation last week. HX's Chair Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, says Moore is resigning to devote more time to working with growth-stage companies as a mentor, adviser, and investor.

"In a rapidly growing and evolving landscape like this one, we must ensure resources are leveraged for greatest impact," Burger says. "The HX executive committee believes now is an appropriate time re-strategize with the HX organization to ensure it is aligned with the current needs of the innovation ecosystem. While changes may be called for to place resources where they can do the most good, there remains a need for a broad ecosystem champion and HX will continue to serve in that role." Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy

Houston founder talks growth and innovation in the pharmaceuticals industryShaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

Shaun Noorian founded Empower Pharmacy so he could create a business that was service focused, and now the company has grown and expanded — and is now working on building two new 85,000-square-foot facilities in Houston. Noorian, in a Q&A with InnovationMap, explained that Houston has been integral to his success.

"I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation," Noorian tells InnovationMap. "I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow.

"Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs," he continues. "Having a diverse workforce has been integral in our growth." Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

Houston founder talks growth and innovation in the pharmaceuticals industry

Q&A

When Shaun Noorian encountered what he felt was a poorly ran process, as an engineer, he built something better. Now, he runs one of the nation's largest compounding pharmacies that's at a pivotal time for growth.

Headquartered in Houston, Empower Pharmacy is opening two new facilities locally — one debuts later this year and the other in 2022. Ahead of this milestone for his company, Noorian joined InnovationMap for a Q&A about how he decided to start his company and how he's grown it from a small office to two 85,000-square-foot facilities — as well as how Houston has been a big part of his company's success.

InnovationMap: Why did you decide to form Empower Pharmacy?

Shaun Noorian: I initially started Empower Pharmacy as a patient that was frustrated with the medication that I was receiving from a local compounding pharmacy in Houston.

I'd been working as a hydraulic fracturing field engineer at Schlumberger after graduating from college with a degree in mechanical engineering and was injured after several months on the job. I hemorrhaged three of my lower vertebrae and was put into physical therapy to try and fix my back. One of the doctors that was treating me noticed that I was very skinny for my age. I was probably 25 years old at the time. He decided to test my blood for the hormone testosterone, which is responsible for muscle growth and many other important factors in both men and women. The test determined that I had the testosterone level of an elderly man. The doctors sent me to Baylor College of Medicine for MRI blood tests, and they determined that I had a pituitary disorder and that I couldn't create the hormones responsible to tell my body to create testosterone. They put me on testosterone replacement therapy and it completely changed my life. Being testosterone deficient my entire life, I didn't realize what normal should be.When I was put on the medication, it was like a new lease on life. And I became very interested in the medication that I was taking, and how it worked. I studied everything I could. I was getting my medications from a local compounding pharmacy here in Houston, and I wasn't very satisfied with the quality of the service or the costs. Getting these medications was a very large percentage of my, what I was living off of. I couldn't figure out why this medication was so expensive when it cost just a few cents to make.

IM: How did you turn that passion into a business?

SN: I guess like most engineers, I decided I wanted to build — to make my own pharmacy. And make my own drugs and offer them to patients in a manner that I would want to it be from a patient's perspective when dealing with the compound pharmacy. I leased about 100 square feet in the back of the doctor's office. I pretty much converted one of his exam rooms and started my pharmacy there. I hired a pharmacist and did all the technician duties myself. I wanted to apply the patient experience that I would've wanted.

Slowly but surely, patients and prescribers around the area were very happy with the level of service and quality that they were receiving from our pharmacy. And we would get more requests through simple word of mouth and reputation. We grew pretty quickly out of that space and then built out a 1,500-square-foot space in a shopping center a couple of years later.

Following several more expansions and new locations throughout the years, we're now gearing up to open our new facility (7601 N. Sam Houston Parkway W., near the intersection of Highway 249 and Beltway 8), which will be the most advanced compounding pharmacy ever built. It has a lot of automation, and utilizes the same processes and equipment that Big Pharma uses to make their drugs. We're trying to better the system and continue to bring automation into the compounding industry so we can continue to scale and set a standard for the rest of the industry.

IM: What sets your business apart from what else is out there?

SN: We're a pharmacy that wants to do everything in house. We want to integrate our supply chain, and that means removing low value middleman from the health care ecosystem and streamline the medical distribution process. This means being the manufacturer, distributor, and regional pharmacy all in one, so we can really control our supply chain and integrate it. And at the same time, we can really be able to control and customize the consumer experience for both our patients and prescribers in a way that we would want. It's been a lot of fun being able to create your own healthcare ecosystem and building software for that your for patients that I'd want to use.

I'm an engineer. It's more fun talking about my equipment than anything else.

If you walk into a Walgreens, it's a simple repackaging operation. You're taking pills from a big bottle and putting them in a smaller bottle. What differentiates us from them and what's unique about this facility is that it's really built the same way as traditional pharmaceutical manufacturing is built using the same exact processes, systems, layout, etc.

We create our own purified water. We create our own clean, dry compressed air. We create our own clean steam that we use in our compounding processes, which are built to CGMP — current good manufacturing practices — specifications. We adopt a lot of those processes into the facility, and we built the facility around those standards that the FDA requires.

IM: You mentioned a new facility — but Empower is actually opening two new facilities within a year of each other. Tell me about those.

SN: Each facility is a mirror of each other — they are both 85,000 square feet. The one that's opening this year is going to be a pharmacy, so it'll just be dealing with patients. The next one is going to be licensed with the FDA and will work with larger institutions, selling medications in bulk for office use to institutions, hospitals, clinics, and prescribers. They will administer those medications to their patients in office. It's our way of being able to integrate that supply chain, so we can be that one-stop shop. So, physicians don't have to go to different vendors to source their medications — we can be an all-encompassing partner and vendor for them to source all their medical needs.

IN: How else are you expanding your business model?

SN: We've always concentrated on — since the inception of the company — quality, service, and cost. And we're always working to figure out how to increase quality, how to decrease costs, and how to make it easier and more convenient for our customers to use us. Some projects that we've been working on that are set to launch in the next few years is building out our own API – application programming interface – so that our telemedicine and other clients that are using electronic versions of health care record software can easily interface with our systems and vice versa.

IM: How has Houston been for you as a home base for Empower?

SN: I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation. It's really just a lot of luck of being in Houston. I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow. Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs. Having a diverse workforce has been integral in our growth. Also, having two schools of pharmacy in our backyard has also helped.

There's a reason why, as we grow, we always stay in Houston. It doesn't make sense for us to go anywhere else. This is a great city and a great state to do business.

IM: Are you hiring?

Oh, we're always hiring. I think we currently have around 50 positions open and there's everything from pharmacy operations, all the way to manufacturing and marketing to sales, logistics, legal, you name it.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.

View All Listings